Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro

We’ll find out any day now when the company discloses all-important mid-stage data on an oral medicine it hopes can compete with the heirs to Wegovy and Mounjaro.

The drug, danuglipron, is a twice-daily pill that targets GLP-1, the biological target that has upended the drug industry and shifted billions of dollars of value on the stock market.